These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
139 related items for PubMed ID: 11989083
1. [Malignant neuroleptic syndrome and hyponatremia associated with risperidone poisoning]. Epelde Gonzalo F. An Med Interna; 2002 Jan; 19(1):50. PubMed ID: 11989083 [No Abstract] [Full Text] [Related]
6. A Case of neuroleptic malignant syndrome accompanied to an atypical antipsychotic agent: risperidone. Pasa S, Sayhan MB, Boyraz T, Urakci Z, Altintas A. Neurotoxicology; 2008 Jul 15; 29(4):750-1. PubMed ID: 18539333 [No Abstract] [Full Text] [Related]
7. [Neuroleptic malignant syndrome in users of risperidone]. van Bemmel T, Westendorp RG. Ned Tijdschr Geneeskd; 2005 Mar 12; 149(11):608; author reply 608. PubMed ID: 15799646 [No Abstract] [Full Text] [Related]
8. [Neuroleptic malignant syndrome in users of risperidone]. Vorel SK, Bos F, Vorel-Havelkova E, Brombacher PJ. Ned Tijdschr Geneeskd; 2005 Jan 15; 149(3):159-60; author reply 160. PubMed ID: 15693596 [No Abstract] [Full Text] [Related]
9. [Neuroleptic malignant syndrome in users of risperidone]. Kroon JG. Ned Tijdschr Geneeskd; 2005 Jan 15; 149(3):157-8; author reply 158. PubMed ID: 15693594 [No Abstract] [Full Text] [Related]
10. [Neuroleptic malignant syndrome in users of risperidone]. van Waarde JA, Kuiper J, Verwey B. Ned Tijdschr Geneeskd; 2005 Jan 15; 149(3):156-7; author reply 157. PubMed ID: 15693593 [No Abstract] [Full Text] [Related]
11. [Neuroleptic malignant syndrome in users of risperidone]. Gerritsen AA, de Jonghe-Rouleau AP, Stienstra-Liem LH. Ned Tijdschr Geneeskd; 2004 Sep 11; 148(37):1801-4. PubMed ID: 15495506 [Abstract] [Full Text] [Related]
12. Potentiating effect of fluphenazine decanoate and risperidone on development of neuroleptic malignant syndrome. Liu PY, Wu PC, Chen CY, Chen YC. Gen Hosp Psychiatry; 2011 Sep 11; 33(1):84.e5-7. PubMed ID: 21353143 [Abstract] [Full Text] [Related]
13. A case study: neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation. Ochi S, Kawasoe K, Abe M, Fukuhara R, Sonobe K, Kawabe K, Ueno S. Gen Hosp Psychiatry; 2011 Sep 11; 33(6):640.e1-2. PubMed ID: 21749835 [Abstract] [Full Text] [Related]
14. Neuroleptic malignant syndrome in the burns patient? Cawrse N, Wilson S, Williams M, Burge T. Burns; 2006 Aug 11; 32(5):647-9. PubMed ID: 16777336 [No Abstract] [Full Text] [Related]
15. Risperidone-induced hyperamylasemia, hyperlipasemia, and neuroleptic malignant syndrome: a case report. Ghio L, Fornaro G, Rossi P. J Clin Psychopharmacol; 2009 Aug 11; 29(4):391-2. PubMed ID: 19593182 [No Abstract] [Full Text] [Related]
16. Catatonia and mild neuroleptic malignant syndrome after initiation of long-acting injectable risperidone: case report. Mall GD, Hake L, Benjamin AB, Adityanjee A. J Clin Psychopharmacol; 2008 Oct 11; 28(5):572-3. PubMed ID: 18794658 [No Abstract] [Full Text] [Related]
17. Neuroleptic malignant syndrome associated with risperidone long-acting injection: a case report. Yamashita T, Fujii Y, Misawa F. J Clin Psychopharmacol; 2013 Feb 11; 33(1):127-9. PubMed ID: 23288234 [No Abstract] [Full Text] [Related]
19. Caution is still needed when prescribing atypical antipsychotics. Carey S. Br J Hosp Med (Lond); 2008 May 11; 69(5):299. PubMed ID: 18557562 [No Abstract] [Full Text] [Related]